Layla review

Layla for mothers: our verdict

Standing monthly rates of $199 for compounded semaglutide and $299 for compounded tirzepatide, each fronted by a $99 first-month promotion that is the number the marketing actually leads with. Read live on August 21, 2026, the plan cards say it plainly — "Starting at $99 / 1st Month (Originally $199 / month)" — so the discount is real and it lasts exactly one month. Two things sit alongside it that a reader should see. Quarterly plans are also offered at $297 and $449 and are labeled per month on the card, which cannot be reconciled against the cheaper monthly plans from the public page alone, so those figures are not asserted here. And the page was running a Cyber Week banner with a fifty-percent-off countdown reading zero hours, zero minutes and zero seconds — in August. Against that, its disclosure is better than most: three operating entities are named, including the prescribing practices Beluga Health, P.A. and Pennsylvania Medical, P.C., and none of the three has an FDA warning letter. It runs about $199/month.

We weigh Layla the way mothers actually have to: not just the monthly cost, but postpartum and breastfeeding timing and PCOS and insulin resistance — the parts a general weight-loss roundup leaves out.

What Layla costs, in full

• Compounded semaglutide — Injection: $199/mo
• Compounded tirzepatide — Injection: $299/mo

That lands within a few dollars of the ~$179/month median across the providers we track, so the monthly cost isn't what should decide this one either way. Weigh it instead on postpartum and breastfeeding timing and PCOS and insulin resistance, and on what the price actually includes — a lower number that leaves out labs, visits or shipping is not the cheaper option.

On that last point Layla is no help: it doesn't break down what the monthly figure covers — whether the provider visit, shipping and any lab work are inside it or billed separately. Ask before you pay, because that answer is what decides whether a mid-range price is actually mid-range.

The medications Layla prescribes

Layla prescribes semaglutide and tirzepatide — the two with the largest published weight-loss effects, and carrying both on one account matters when insulin resistance, common with PCOS and after gestational diabetes, makes tirzepatide the better-suited option. These are compounded formulations from a licensed pharmacy — the reason the price stays down — but compounded GLP-1s aren't FDA-approved finished products the way Wegovy and Zepbound are.

Where Layla fits — and where it doesn't — for mothers

A good fit if…

• switching between semaglutide and tirzepatide may become necessary as your body and your hormones change.

Look elsewhere if…

• you specifically want an FDA-approved brand pen with its own pregnancy and lactation labeling.
• you'd rather a prescriber talk through timing around postpartum and breastfeeding timing — that is the ground our #1 pick, CoreAge Rx, is built on.

Oversight, safety, and what we could verify

Our confidence is moderate — the core facts check out, but some details (per-state availability, program mechanics) aren't fully public. As with any compounded GLP-1, the most useful thing mothers can do is confirm which licensed pharmacy fills the prescription and what's in the formulation — we explain how we weigh oversight in our scoring methodology.

One line that applies to every provider on this site: no GLP-1 is established as safe in pregnancy or while breastfeeding, and the labels advise against use. This is a review of a commercial program, not a green light — the timing decision belongs to you and your clinician.

The bottom line

Layla is a reasonable option — weigh it on postpartum and breastfeeding timing and PCOS and insulin resistance against the alternatives below. For most mothers, CoreAge Rx remains the stronger all-round fit — see why it tops our ranking.